Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism

BACKGROUND: Direct-acting oral anticoagulants (DOACs) are alternatives to low molecular weight heparin (LMWH) in most cancer-associated thrombosis (CAT) patients. OBJECTIVES: This study sought to compare the effectiveness and safety of rivaroxaban and LMWH for venous thromboembolism (VTE) treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Craig I., Caroti, Kimberly Snow, Abdelgawwad, Khaled, Psaroudakis, George, Fatoba, Samuel, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Khorana, Alok A., Becattini, Cecilia, Lee, Agnes Y.Y., Ekbom, Anders, Carrier, Marc, Brescia, Christopher, Cohen, Alexander T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Mini-Focus Issue: Bleeding, Thrombosis, and Atrial Fibrillation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152194/
https://www.ncbi.nlm.nih.gov/pubmed/37144109
http://dx.doi.org/10.1016/j.jaccao.2022.10.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152194/
https://www.ncbi.nlm.nih.gov/pubmed/37144109
http://dx.doi.org/10.1016/j.jaccao.2022.10.014

Ejemplares similares